ea0011p433 | Endocrine disruptors | ECE2006
Colao A
, Bouterfa H
, Cappabianca P
, Caron P
, De Menis E
, Farrall A
, Gadelha M
, Reed A
, Reincke M
, Safari M
, TSjoen G
, Cuneo R
This is the first prospective study to compare the efficacy and safety of medical therapy and surgery as primary therapy in acromegaly.A total of 104 patients with untreated acromegaly were enrolled. Eighty-one patients randomized to receive either octreotide LAR 20 mg (n=40) or surgery (n=41) completed the 48 weeks treatment period, and constituted the population used for this analysis, regardless of response to treatment.<p class="abs...